Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9402-25-Q-9404

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

San Antonio, Texas, UNITED STATES

SourceSAM
The Defense Health Agency (DHA), acting on behalf of the Department of Defense (DoD), has issued a solicitation (Procurement Identifier: HT9402-25-Q-9404) for the establishment of Uniform Formulary Blanket Purchase Agreements (UF BPAs) and participation in the Uniform Formulary Additional Discount Program (UF ADP). This procurement is a critical component of the DoD’s statutory mandate under 10 U.S.C. § 1074g and its implementing regulation (32 CFR § 199.21) to maintain an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). The program’s primary objective is to ensure the availability of clinically effective and cost-efficient pharmaceutical agents to eligible beneficiaries across the MHS. The scope of this solicitation encompasses the acquisition of pharmaceutical agents within specific drug classes identified for potential placement on the DoD Uniform Formulary (UF). The UF is determined through a rigorous review process by the DoD Pharmacy and Therapeutics (P&T) Committee, which evaluates the relative clinical and cost effectiveness of agents within each therapeutic class. The outcome of this process informs the classification of drugs as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF), which in turn impacts cost-sharing and access for beneficiaries. For the November 2025 P&T Committee meeting, the following newly approved drugs will be reviewed for potential inclusion on the UF: - Blujepa (Antibiotics) - Brekiya (Migraine Agents) - Dawnzera (Corticosteroids-Immune Modulators; Hereditary Angioedema Agents) - escitalopram (Antidepressants and Non-opioid Pain Syndrome Agents; Selective Serotonin Reuptake Inhibitors) - Exxua (Antidepressants and Non-opioid Pain Syndrome Agents) - Leqembi IQLIK (Alzheimer’s Agents) - ustekinumab-ttwe (Targeted Immunomodulatory Biologics; Interleukin 23) - Wayrilz (Hematological Agents; Platelets) - Zurnai (Alcohol Deterrents-Narcotic Antagonists) - Phyrago (Oncological Agents; Chronic Myelogenous Leukemia) - Inluriyo (Breast Cancer Agents; Estrogen Receptor Antagonist) - Enbumyst (Diuretics) The solicitation package, including the RFQ and appendices for both the UF BPA and UF ADP, provides detailed instructions, submission requirements, and important deadlines. Contractors are advised to review these documents thoroughly to ensure compliance with all procedural and technical requirements. Notably, a pre-quotation teleconference is scheduled for October 15, 2025, as outlined in Part 2.4 of the RFQ. Prospective offerors are encouraged to participate in this session to clarify any questions regarding the solicitation. Additionally, responses to clinical questions specified in Part 3.4 must be submitted via email to the designated point of contact by the deadline indicated in Part 2.3.2. This opportunity is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505 (Drugs and Biologicals). There are no set-aside restrictions; the solicitation is open to all qualified entities capable of meeting the DoD’s requirements. The place of performance is San Antonio, Texas, United States. The contracting entity for this procurement is the Defense Health Agency, a federal office responsible for managing the MHS pharmacy benefits program. The primary point of contact for this solicitation is Keith Marasigan, who can be reached at [email protected] for all inquiries and submission of required documentation. Interested contractors should note the following key details: - Solicitation Type: Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) - No set-aside; open competition - Place of Performance: San Antonio, TX, USA - Response Deadline: October 27, 2025, 17:10 - All relevant documents and instructions are available via the SAM.gov opportunity listing (Opportunity ID: 41d1ca6915d8421ea65f49a0de162da5) This procurement represents a significant opportunity for pharmaceutical manufacturers and suppliers with products in the specified therapeutic classes to participate in the DoD’s pharmacy benefits program. Successful contractors will be expected to provide competitive pricing, support the DoD’s clinical and cost-effectiveness objectives, and comply with all regulatory and programmatic requirements as outlined in the solicitation documents. Contractors are encouraged to review all attachments and participate in the pre-quotation teleconference to ensure a comprehensive understanding of the program’s expectations and deliverables.
Documents17